An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Endocrine Therapeutic Strategies for Patients with Hormone

Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors

Pharmaceutics, Free Full-Text

Resistance to endocrine therapy in HR + and/or HER2 + breast

Next-generation selective estrogen receptor degraders and other

6.7 Neoadjuvant Therapy

Frontiers Therapeutic evolution in HR+/HER2- breast cancer: from

Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene

Randomized Phase II Trial of Fulvestrant Plus Everolimus or

Selective RET Inhibitors for RET Fusion-Positive Non-Small Cell Lung Cancer - Cancer Therapy Advisor

Cancer Clinical Trials

Antimicrobial and antitumor properties of anuran peptide temporin

Endocrine Therapy in Breast Cancer: Making Sense of the 'Word

Oncology - European Medical Journal

The Burgeoning Significance of Liquid-Liquid Phase Separation in